Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMBINED ADMINISTRATION OF A 5-HYDROXYTRYPTAMINE (5-HT)(1D) ANTAGONIST AND A 5-HT REUPTAKE INHIBITOR SYNERGISTICALLY INCREASES 5-HT RELEASEIN GUINEA-PIG HYPOTHALAMUS IN-VIVO
Autore:
ROLLEMA H; CLARKE T; SPROUSE JS; SCHULZ DW;
Indirizzi:
PFIZER INC,DIV CENT RES GROTON CT 06340
Titolo Testata:
Journal of neurochemistry
fascicolo: 5, volume: 67, anno: 1996,
pagine: 2204 - 2207
SICI:
0022-3042(1996)67:5<2204:CAOA5(>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
DORSAL RAPHE NUCLEUS; EXTRACELLULAR LEVELS; RECEPTOR ANTAGONIST; AUTORECEPTORS; BRAIN; MICRODIALYSIS; INVIVO; DEPRESSION; CITALOPRAM; PINDOLOL;
Keywords:
MICRODIALYSIS; 5-HYDROXYTRYPTAMINE; SEROTONIN; 5-HT1D RECEPTOR ANTAGONISTS; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; ANTIDEPRESSANT; GUINEA PIG HYPOTHALAMUS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
H. Rollema et al., "COMBINED ADMINISTRATION OF A 5-HYDROXYTRYPTAMINE (5-HT)(1D) ANTAGONIST AND A 5-HT REUPTAKE INHIBITOR SYNERGISTICALLY INCREASES 5-HT RELEASEIN GUINEA-PIG HYPOTHALAMUS IN-VIVO", Journal of neurochemistry, 67(5), 1996, pp. 2204-2207

Abstract

In vivo microdialysis in guinea pig hypothalamus was used to study the effect of serotonin [5-hydroxytryptamine (5-HT)] subtype 1D autoreceptor blockade on the increase in extracellular 5-HT levels produced bya selective 5-HT reuptake inhibitor (SSRI). Administration of the selective 5-HT1D antagonist GR127935 at 0.3 mg/kg had no effect, but 5 mg/kg significantly increased extracellular levels of 5-HT and 5-hydroxyindoleacetic acid to 135% of basal values. Moreover, at these doses GR127935 significantly attenuated the decrease in extracellular 5-HT levels following local perfusion with the selective 5-HT1D agonist CP-135,807. The SSRI sertraline at 2 mg/kg increased 5-HT levels to 130% of basal levels. The combination of this low doss of sertraline with either dose of GR127935 resulted in a pronounced, long-lasting increase in5-HT levels to 230% of basal values. These results indicate that the effects of an SSRI on terminal 5-HT are significantly enhanced by coadministration of a 5-HT1D antagonist and confirm that in addition to somatodendritic 5-HT1A autoreceptors, terminal 5-HT1D autoreceptors mitigate the effect of SSRls on terminal 5-HT. As such, antagonists of the5-HT1D autoreceptor could be useful as rapidly acting antidepressantsand may shorten the onset of antidepressant action when combined withSSRls.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 00:31:22